Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Факторы прогноза в определении объема операции при дифференцированном раке щитовидной железы
Факторы прогноза в определении объема операции при дифференцированном раке щитовидной железы
В.Ж.Бржезовский, В.Л.Любаев, Г.Ю.Кочурина, С.Субраманиан. Факторы прогноза в определении объема операции при дифференцированном раке щитовидной железы. Онкология. 2006; 3: 35-36.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. DeGroot Lj, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414–24.
2. Eroglu A, Berberoglu U, Burruk F. Completion thyroidectomy for differentiated thyroid carcinoma. J Surg Oncol 1995; 59 (4): 261–7.
3. Nakamura T, Yana I, Kabayashi T et al. p53 gene mutations associated with anaplastic transformations of human thyroid carcinomas. Jpn J Cancer Res 1992; 83: 1293–8.
4. Loh KC, Greenspan FS, Gee L et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82: 3553–62.
5. Herranz-gonzalez J, Gavilan J, Martinez-Vidal J, Gavilan C. Comlications following thyroid surgery. Arch Otolaryngol Head and Neck Surg 1991; 117: 516–8.
6. Wilson DB, Staren ED, Prinz RA. Thyroid reoperations: indications and risk. Am Surg 1998; 64: 674–8; discussion 678–9.
7. Bohm J, Kosma VM, Eskelinen M et al. Non-Suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. Eur J Endocrinol 1999; 141: 560–7.
8. Duren M, Siperstein AE, Shen W et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 1999; 126: 13–19 thyroid.
9. Samaan NA, Schults PN, Hickey RC et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1,599 patients. J Clin Endocrinol Metab 1992; 75: 714–20.
10. Пачес А.И., Пропп Р.М. Рак щитовидной железы. М.
11. Романчишен В.Ф. Клиническое обоснование показаний к оперативному лечению заболеваний щитовидной железы. Вестн. хир. 1994; 1–2: 3–6.
12. Grant CS, Hay ID, Gough IR et al. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 1988; 104: 954–62.
13. Cohn KH, Backdahl M, Forsslung G et al. Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy. Surgery 1984; 96: 957–71.
14. Sosa JA, Bowman HM, Tielsch JM et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228: 320–30.
15. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer (see comments;published erratum appears in Am J Med 1995; 98: 215). Am J Med 1994; 97: 418–28.
16. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104: 947–53.
17. Hay ID, Bergstralh EJ, Goellner JR et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1,779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050–7; discussion 1057–8.
2. Eroglu A, Berberoglu U, Burruk F. Completion thyroidectomy for differentiated thyroid carcinoma. J Surg Oncol 1995; 59 (4): 261–7.
3. Nakamura T, Yana I, Kabayashi T et al. p53 gene mutations associated with anaplastic transformations of human thyroid carcinomas. Jpn J Cancer Res 1992; 83: 1293–8.
4. Loh KC, Greenspan FS, Gee L et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82: 3553–62.
5. Herranz-gonzalez J, Gavilan J, Martinez-Vidal J, Gavilan C. Comlications following thyroid surgery. Arch Otolaryngol Head and Neck Surg 1991; 117: 516–8.
6. Wilson DB, Staren ED, Prinz RA. Thyroid reoperations: indications and risk. Am Surg 1998; 64: 674–8; discussion 678–9.
7. Bohm J, Kosma VM, Eskelinen M et al. Non-Suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. Eur J Endocrinol 1999; 141: 560–7.
8. Duren M, Siperstein AE, Shen W et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 1999; 126: 13–19 thyroid.
9. Samaan NA, Schults PN, Hickey RC et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1,599 patients. J Clin Endocrinol Metab 1992; 75: 714–20.
10. Пачес А.И., Пропп Р.М. Рак щитовидной железы. М.
11. Романчишен В.Ф. Клиническое обоснование показаний к оперативному лечению заболеваний щитовидной железы. Вестн. хир. 1994; 1–2: 3–6.
12. Grant CS, Hay ID, Gough IR et al. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 1988; 104: 954–62.
13. Cohn KH, Backdahl M, Forsslung G et al. Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy. Surgery 1984; 96: 957–71.
14. Sosa JA, Bowman HM, Tielsch JM et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228: 320–30.
15. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer (see comments;published erratum appears in Am J Med 1995; 98: 215). Am J Med 1994; 97: 418–28.
16. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104: 947–53.
17. Hay ID, Bergstralh EJ, Goellner JR et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1,779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050–7; discussion 1057–8.
Авторы
В.Ж.Бржезовский, В.Л.Любаев, Г.Ю.Кочурина, С.Субраманиан
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.